Fortrea Holdings Inc. (FTRE) stock
FTRENasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 4/3056% above fair value
$20.50+0.91 (+4.65%)
Close on Nov 18, 2026Market cap $1.98BP/E –Yield –
Fortrea revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Fortrea's revenue for the twelve months ending Sep 30, 2026 was $2.67B, down 3.4% year over year. For fiscal 2025 it was $2.72B, up 1.0% from the year before. The highest annual figure on record is $3.06B in fiscal 2021.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.72B | +1.0% |
| FY2024 | Dec 31, 2024 | $2.70B | -5.1% |
| FY2023 | Dec 31, 2023 | $2.84B | +0.2% |
| FY2022 | Dec 31, 2022 | $2.84B | -7.2% |
| FY2021 | Dec 31, 2021 | $3.06B | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $691.50M | -1.4% |
| Q2 FY2026 | Jun 30, 2026 | $678.20M | -4.5% |
| Q1 FY2026 | Mar 31, 2026 | $636.50M | -2.3% |
| Q4 FY2025 | Dec 31, 2025 | $660.50M | -5.2% |
| Q3 FY2025 | Sep 30, 2025 | $701.30M | +3.9% |
| Q2 FY2025 | Jun 30, 2025 | $710.30M | +7.2% |
| Q1 FY2025 | Mar 31, 2025 | $651.30M | -1.6% |
| Q4 FY2024 | Dec 31, 2024 | $697.00M | -1.8% |
| Q3 FY2024 | Sep 30, 2024 | $674.90M | -5.4% |
| Q2 FY2024 | Jun 30, 2024 | $662.40M | -8.6% |
| Q1 FY2024 | Mar 31, 2024 | $662.10M | -4.6% |
| Q4 FY2023 | Dec 31, 2023 | $709.70M | +41.2% |
| Q3 FY2023 | Sep 30, 2023 | $713.80M | -6.4% |
| Q2 FY2023 | Jun 30, 2023 | $725.10M | -8.6% |
| Q1 FY2023 | Mar 31, 2023 | $693.90M | – |
| Q4 FY2022 | Dec 31, 2022 | $502.60M | – |
| Q3 FY2022 | Sep 30, 2022 | $762.30M | – |
| Q2 FY2022 | Jun 30, 2022 | $793.10M | – |
See a number that looks wrong?